A Phase I Open Label/Phase II Randomized, Double-Blind, Multicenter Trial Investigating the Combination of Everolimus and TransArterial ChemoEmbolisation (TACE) With Doxorubicin in Patients With Hepatocellular Carcinoma.

Trial Profile

A Phase I Open Label/Phase II Randomized, Double-Blind, Multicenter Trial Investigating the Combination of Everolimus and TransArterial ChemoEmbolisation (TACE) With Doxorubicin in Patients With Hepatocellular Carcinoma.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 09 Jul 2015

At a glance

  • Drugs Everolimus (Primary) ; Doxorubicin
  • Indications Liver cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Jul 2015 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
    • 15 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 13 Jan 2014 Planned End Date changed from 1 Sep 2013 to 1 Mar 2016 as per ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top